Independent Monitoring Board Recommends Early Termination of Ebola Therapeutics Trial in DRC Because of Favorable Results with Two of Four Candidates | NIH: National Institute of Allergy and Infectious Diseases

Independent Monitoring Board Recommends Early Termination of Ebola Therapeutics Trial in DRC Because of Favorable Results with Two of Four Candidates | NIH: National Institute of Allergy and Infectious Diseases

Tuesday, August 13, 2019 Two Ebola Therapeutics Show Favorable Results in Clinical Trial Preliminary results in a clinical trial of investigational Ebola therapeutics in the Democratic Republic of the Congo indicated that those individuals receiving the investigational treatments REGN-EB3 or mAb114 had a greater chance of survival compared to those participants in the other two treatment arms. The independent Data and Safety Monitoring Board (DSMB) recommended that the study be stopped and that all future patients be randomized to receive either REGN-EB3 or mAb114 in what is being considered an extension phase of the study.